Drug intelligence / Profile preview

Majiazi

Development stage: Unknown
Lead developer: Chengdu Majiazi Biotechnology
Administration: Oral

Overview

Majiazi (Majiazi Capsule) is an investigational botanical drug candidate developed by Chengdu Majiazi Biotechnology for the treatment of advanced solid tumors. It is derived from the plant *Paliurus hemsleyanus*, which has a history of use in traditional medicine. The drug is currently being evaluated in a Phase 1, open-label, single-arm clinical trial in China (CTR20241028) to assess its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors who have failed or are intolerant to standard therapies. Preliminary research into *Paliurus hemsleyanus* extracts suggests potential anti-tumor activity through the induction of apoptosis and inhibition of cancer cell proliferation.

Other names: Majiazi Capsule马甲子胶囊

Targets

Claudin 18.2

Beyond the preview

Go deeper on Majiazi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Majiazi.

Explore the full profile